- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04065438
Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System (FSGSALLAGE)
Treatment of Drug-resistant Adult and Pediatrc Primary Focal Segmental Glomerulosclerosis and Post -Transplant Recurrence Using the LIPOSORBER® LA-15 System
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study will enroll up to 35 adult patients at 3-10 clinical sites. The duration of the treatment phase of the study will take approximately 9 weeks for a total of 12 apheresis treatments with the LIPOSORBER® LA-15 System; the treatments will be given twice weekly for 3 weeks followed by once weekly for 6 weeks. Patients will undergo follow-up at 1, 3, 6, 12, and 24 months after the final apheresis treatment.
This study is conducted as a Post Approval Study imposed by Humanitarian Device Exemption (HDE) order to confirm the safety and efficacy of the LIPOSORBER® LA-15 System in the treatment of drug-resistant primary FSGS and post Transplant recurrence.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Laleh Abedin, MD
- Phone Number: 6469846538
- Email: laleh.abedinzadeh@kaneka.com
Study Contact Backup
- Name: Ayaka Kitamura
- Email: Ayaka.Kitamura1@kaneka.co.jp
Study Locations
-
-
California
-
Loma Linda, California, United States, 92354
- Recruiting
- Loma Linda University Hospital
-
Contact:
- Amir Abdipour, MD
-
Contact:
- Daisy Sekly
- Email: DSekly@llu.edu
-
Loma Linda, California, United States, 92354
- Recruiting
- Loma Linda University Children'S Hospital
-
Contact:
- Cheryl P Sanchez-Kazi, MD
-
-
Delaware
-
Wilmington, Delaware, United States, 19803
- Recruiting
- Nemours/Alfred I DuPont Hospital for Children
-
Contact:
- Joshua J Zaritsly, MD
- Phone Number: 302-651-5527
- Email: joshua.zaritsky@nemours.org
-
-
Michigan
-
Grand Rapids, Michigan, United States, 49503
- Recruiting
- Helen DeVos Children's Hospital
-
Contact:
- Alejandro Quiroga, MD
-
-
New York
-
New York, New York, United States, 10065
- Recruiting
- Weill Cornell Medicine / NewYork-Presbyterian
-
Contact:
- Eduardo M Perelstein, MD
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- Recruiting
- University of North Carolina
-
-
Ohio
-
Akron, Ohio, United States, 44308
- Recruiting
- Akron Children's Hospital
-
Contact:
- Rupesh Raina, MD
- Phone Number: 330-543-0702
- Email: apokelsek@akronchildrens.org
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Recruiting
- Medical University of South Carolina
-
Contact:
- Linda Walker
- Phone Number: 843-792-6109
- Email: walkerlp@musc.edu
-
Charleston, South Carolina, United States, 29425
- Recruiting
- Medical University of South Carolina Children's Hospital
-
Contact:
- Katherine E Twombley, MD
-
-
Virginia
-
Richmond, Virginia, United States, 23298
- Recruiting
- Children's Hospital of Richmond at VCU
-
Contact:
- Megan M Lo, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
A patient is deemed suitable for inclusion in the study if the patient has nephrotic syndrome associated with primary FSGS when:
• Standard treatment options, including corticosteroid and/or calcineurin inhibitors, are unsuccessful or not well tolerated and the patient's glomerular filtration rate (GFR) ≥ 45 ml/min/1.73 m2.
or
• The patient is post renal transplantation.
Exclusion Criteria:
General Exclusion Criteria
- Patient is greater than 75 years of age at the start of the treatment period or less than 22
- The patient is unwilling or unable to sign and date the informed consent
- Pregnant, lactating, or planning to become pregnant prior to completing the study (Note: The safety of the use of LIPOSORBER® in pregnant women has not been studied. There may be unknown risks to an embryo/fetus. Sexually active women of childbearing potential should avoid pregnancy during the use of the LIPOSORBER device and throughout the study duration.)
- Unable or unwilling to comply with the follow-up schedule
- Simultaneously participating in another investigational drug or device study
- Body weight < 15 kg (33.1 lbs)
Medical Exclusion Criteria
- Currently being administered ACE inhibitors that cannot be withheld for at least 24 hours prior to each apheresis treatment (Note: The time period to withhold ACE inhibitors should be prolonged, if determined by the treating physician, considering each individual's renal function and the biological half-life of the ACE-inhibitor currently in use.)
- Currently being administered antihypertensive drugs other than ACE inhibitors (e.g., ARBs) that cannot be withheld on the day of apheresis until after the procedure
- Medical condition or disorder that would limit life expectancy to less than the primary clinical study endpoint or that may cause noncompliance with the study plan or confound the data analysis
- Hypersensitivity to dextran sulfate, heparin, or ethylene oxide
- Adequate anticoagulation cannot be achieved due to severe hemophilia, severe hemorrhage diathesis, severe gastrointestinal ulcers, or are recipients of vitamin K antagonist medications
- Extracorporeal circulation therapy with LIPOSORBER® LA-15 System cannot be tolerated due to severe cardiac insufficiency, acute myocardial infarction, severe cardiac arrhythmia, acute apoplexy, severe uncontrollable hypertension, or severe uncontrollable hypotension Note: Severe uncontrollable hypotension/hypertension indicates the cases with systolic and/or diastolic blood pressure ≤ 5th percentile for age, gender, and height.
- Cardiac impairments such as uncontrolled arrhythmia, unstable angina, decompensated congestive heart failure, or valvular disease
- Functional thyroid disease or liver abnormalities
- Unresolved systemic or local infection that could affect the clinical study outcomes
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LIPOSORBER® LA-15 System
All study patients who meet the study eligibility criteria will undergo the extracorporeal treatment using LIPOSORBER® LA-15 System.
The participants are to be treated with the system twice weekly for the 3weeks and then once weekly for the following 6 weeks.
|
LIPOSORBER® LA-15 is a blood purification therapy; selectively removes apoprotein B-containing lipoproteins such as LDL from circulating blood and rapidly reduces the plasma cholesterol level. It was originally developed for prevention of coronary atherosclerosis progression in patients with serious hyperlipidemia such as familial hypercholesterolemia. In the late 1980's, LDL-A was used to improve dyslipidemia in Nephrotic Syndrome, initially to prevent organ damage. LDL-A was found to improve both the dyslipidemic condition and clinical symptoms (proteinuria and hypoproteinemia). |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate the safety and probable benefit of the LIPOSORBER® LA-15 System in relieving nephrotic syndrome associated with primary FSGS at 1 month after the final apheresis treatment. partial remission at 1 month after the final apheresis treatment.
Time Frame: 1 month after the final Apheresis treatment.
|
The primary probable benefit endpoint will be assessed by calculating the percent reduction in Up/c values at screening and at 1 month after the final apheresis.
|
1 month after the final Apheresis treatment.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Nephrotic condition at 1, 3, 6, 12, and 24 months after the final apheresis treatment, including the percentage of patients who obtain complete or partial remission at 3, 6, 12, and 24 months.
Time Frame: 1, 3, 6, 12, and 24 months after the final treatment
|
Nephrotic condition will be evaluated in following categories, CR (complete remission), PR (partial remission), or NS (nephrotic syndrome).
|
1, 3, 6, 12, and 24 months after the final treatment
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- KMA-FSGS-H170002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Focal Segmental Glomerulosclerosis
-
Genzyme, a Sanofi CompanyCompletedPrimary Focal Segmental GlomerulosclerosisUnited States, Brazil, Germany, Italy, Spain
-
Nanjing University School of MedicineWithdrawnFocal GlomerulosclerosisChina
-
Complexa, Inc.Medpace, Inc.; MicroConstants; Kidney Research Network, formerly NephCure Accelerating... and other collaboratorsCompletedPrimary Focal Segmental GlomerulosclerosisUnited States
-
National Institute of Diabetes and Digestive and...Genentech, Inc.; Indiana UniversityCompletedFocal Segmental Glomerulosclerosis (FSGS)United States
-
National Institute of Diabetes and Digestive and...The Cleveland ClinicCompleted
-
Mayo ClinicUniversity Health Network, Toronto; National Institute of Diabetes and Digestive... and other collaboratorsCompletedPrimary Focal Segmental GlomerulosclerosisCanada, United States
-
National Institute of Diabetes and Digestive and...Completed
-
Mallinckrodt ARD LLCCompletedIdiopathic Focal Segmental GlomerulosclerosisUnited States, Argentina, Turkey, Peru, Australia, Chile, Mexico
-
NYU Langone HealthNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University... and other collaboratorsCompletedFocal Segmental GlomerulosclerosisUnited States, Canada
-
Northwell HealthTerminatedFocal Segmental Glomerulosclerosis
Clinical Trials on LIPOSORBER® LA-15
-
Japan Community Health Care Organization Sendai...UnknownCholesterol EmbolismJapan
-
Patrick Moriarty, MD, FACP, FACCKaneka Medical America LLCCompletedHeart DecompensationUnited States
-
Kaneka Medical America LLCRecruitingFocal Segmental GlomerulosclerosisUnited States
-
Massachusetts General HospitalKaneka Medical America LLCCompletedPreeclampsiaGermany, United States
-
VA Office of Research and DevelopmentCompletedAcute Coronary Artery SyndromeUnited States
-
VA Office of Research and DevelopmentCompletedAcute Coronary SyndromeUnited States
-
SciVision Biotech Inc.CompletedLidocaine | Hyaluronic Acid | Dermal Filler | Aging Mid-FaceTaiwan
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, FranceCompleted
-
Astellas Pharma IncToray Industries, IncCompleted
-
Mahidol UniversityPacific Health FoundationCompleted